Evidence map›Paper›PMID 31416185›Full record

ArticleSensors (Basel, Switzerland)2019

Rapid Detection of HLA-B*57:01-Expressing Cells Using a Label-Free Interdigitated Electrode Biosensor Platform for Prevention of Abacavir Hypersensitivity in HIV Treatment.

Jianxiong Chan, Gita V Soraya, Lauren Craig, Shah M Uddin, Marian Todaro, Duc H Huynh, Chathurika D Abeyrathne, Lyudmila Kostenko, James McCluskey, Efstratios Skafidas and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sensors (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Jianxiong ChanDepartment of Medicine, Royal Melbourne Hospital, The University of Melbourne, Victoria 3050, Australia.
Gita V SorayaDepartment of Medicine, Royal Melbourne Hospital, The University of Melbourne, Victoria 3050, Australia.
Lauren CraigDepartment of Medicine, Royal Melbourne Hospital, The University of Melbourne, Victoria 3050, Australia.
Shah M UddinDepartment of Medicine, Royal Melbourne Hospital, The University of Melbourne, Victoria 3050, Australia.
Marian TodaroDepartment of Medicine, Royal Melbourne Hospital, The University of Melbourne, Victoria 3050, Australia.
Duc H HuynhDepartment of Electrical and Electronic Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010, Australia.
Chathurika D AbeyrathneDepartment of Electrical and Electronic Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010, Australia.
Lyudmila KostenkoDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Victoria 3010, Australia.
James McCluskeyDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Victoria 3010, Australia.
Efstratios SkafidasDepartment of Electrical and Electronic Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010, Australia.
Patrick KwanDepartment of Medicine, Royal Melbourne Hospital, The University of Melbourne, Victoria 3050, Australia. patrick.kwan@unimelb.edu.au.
The Royal Melbourne Hospital · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pre-treatment screening of individuals for human leukocyte antigens (HLA) HLA-B*57:01 is recommended for the prevention of life-threatening hypersensitivity reactions to abacavir, a drug widely prescribed for HIV treatment. However, the implementation of screening in clinical practice is hindered by the slow turnaround time and high cost of conventional HLA genotyping methods. We have developed a biosensor platform using interdigitated electrode (IDE) functionalized with a monoclonal antibody to detect cells expressing HLA-B*57:01. This platform was evaluated using cell lines and peripheral blood mononuclear cells expressing different HLA-B alleles. The functionalized IDE sensor was able to specifically capture HLA-B*57:01 cells, resulting in a significant change in the impedance magnitude in 20 min. This IDE platform has the potential to be further developed to enable point-of-care HLA-B*57:01 screening.

Indexed as

AbacavirAllelesAntibodies, ImmobilizedAntibodies, MonoclonalBiosensing TechniquesDideoxynucleosidesDrug HypersensitivityElectrochemical TechniquesElectrodesHIV InfectionsHLA-B AntigensHumansLeukocytes, MononuclearAbacavirAntibodies, ImmobilizedAntibodies, MonoclonalDideoxynucleosidesHLA-B*57:01 antigenHLA-B Antigenshuman leukocyte antigenimpedance sensorinterdigitated electrodespharmacogeneticspoint-of-care diagnosticsprotein sensor

Identifiers

PMID31416185
PMCPMC6719006
OpenAlexW2968827137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.